Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23680458 | 0.89 | CASP3 (0.42) | KMT2ASIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL12972289 | 0.88 | PTPN1 (0.47) | PTPN1SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL2734926 | 0.88 | PTPN1 (0.47) | PTPN1SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL13225452 | 0.87 | TLR2 (0.49) | PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL13696901 | 0.87 | TLR2 (0.49) | PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL16450347 | 0.86 | PTPN1 (0.48) | PTPN1KMT2ASIRT5 | |
| SCHEMBL15674187 | 0.86 | PTPN1 (0.49) | PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL29549934 | 0.85 | KMT2A (0.48) | KMT2ASIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL23253718 | 0.84 | PTPN1 (0.50) | PTPN1 | |
| SCHEMBL23286089 | 0.84 | SIRT2 (0.45) | SIRT2SIRT1SIRT3SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128167-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20210230218-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | MABPLEX INTERNATIONAL, LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| WO-2021077317-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREFOR | 烟台迈百瑞国际生物医药股份有限公司 | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128167-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | VIP, DNPEP, PREP | PTPN1 3022/4885KMT2A 2943/4885SIRT2 3512/4885 |
| US-20210230218-A1 | OLIGOPEPTIDE LINKER INTERMEDIATE AND PREPARATION METHOD THEREOF | VIP, DNPEP, PREP | PTPN1 3022/4885KMT2A 2943/4885SIRT2 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.